28.27
-2.04(-6.73%)
Currency In USD
| Previous Close | 30.31 |
| Open | 30.31 |
| Day High | 30.61 |
| Day Low | 27.52 |
| 52-Week High | 32.64 |
| 52-Week Low | 5.49 |
| Volume | 485,416 |
| Average Volume | 524,504 |
| Market Cap | 1.06B |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 28.99 |
| Moving Average 200 Days | 17.48 |
| Change | -2.04 |
Oruka Therapeutics Announces New Board Member and Board Transition
GlobeNewswire Inc.
Dec 11, 2025 9:01 PM GMT
Appoints accomplished commercial leader Chris Martin to its Board of DirectorsMENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics
Oruka Therapeutics Announces $180 Million Private Placement
GlobeNewswire Inc.
Sep 17, 2025 5:02 AM GMT
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases,
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
GlobeNewswire Inc.
Sep 17, 2025 5:00 AM GMT
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorabl